HEALTHCARE DELIVERY

Laboratory parameters associated with prolonged hospital length of stay in COVID-19 patients in Johannesburg, South Africa

J Pillai, P P Mistry, M B Ch; D A le Roux, M B Ch; K S C Motaung, N Dip (Biomed Tech), DTech; M Mokgatlle, B Rad, PhD; P Gaylard, B Sc, PhD; N Cengiz, B Sc, MSc (Med); D Basu, MBBS, PhD

1 Department of Surgery, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
2 Department of Technology Transfer and Innovation, Durban University of Technology, Durban, South Africa
3 Department of Public Health, School of Health Care Sciences, Selukela Mokgatho Health Sciences University, Pretoria, South Africa
4 Data Management and Statistical Analysis, Donald Gordon Medical Centre and University of the Witwatersrand, Johannesburg, South Africa
5 Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
6 Department of Public Health Medicine, Steve Biko Academic Hospital and Faculty of Health Sciences, University of Pretoria, South Africa
7 World Health Organization Collaborating Centre for Social Determinants of Health and Health in All Policies, Pretoria, South Africa

Corresponding author: D Basu (debashis.basu@up.ac.za)

Background. Coronavirus disease (COVID-19) has imposed unprecedented stressors on South Africa (SA)’s healthcare system. Superimposed on the country’s quadruple burden of disease, pandemic-related care further exposes existing inequities. Some of these inequities are specific to hospital-based inpatient services, such as the geographical maldistribution of hospital beds, lack of oxygen supplies and assisted ventilation, and scarcity of trained healthcare workers. Certain high-risk groups, such as individuals with cardiometabolic comorbidity, are likely to develop severe COVID-19 disease requiring hospitalisation with potential for a prolonged length of stay (LoS). It may be helpful for health authorities to identify those at risk for prolonged LoS to facilitate appropriate health systems planning.

Objectives. To identify hospital admission laboratory parameters associated with a hospital stay >14 days in patients with COVID-19 pneumonia.

Methods. A retrospective observational study design was used. Laboratory data were obtained from an SA private laboratory for 642 inpatients with suspected or confirmed COVID-19 pneumonia, comprising 7 months of admission laboratory data from six private hospitals in Johannesburg, Gauteng Province.

Results. Of 642 hospital admissions for pneumonia, 497 were confirmed to have COVID-19 infection (reverse transcription-polymerase chain reaction test positive). In the COVID-19-positive group, hospital LoS was prolonged in 35.4% of admissions. Univariate analysis demonstrated an association with the following risk factors for prolonged LoS: older age; male sex; high serum creatinine, sodium (Na), chloride, potassium and urea levels and low estimated glomerular filtration rate; raised white blood cell count, lymphopenia, neutrophilia and an elevated neutrophil-to-lymphocyte ratio (NLR); and elevated levels of D-dimers, interleukin-6 (IL-6), and procalcitonin (PCT). The strongest univariate associations (relative risk (RR) ≥2.0) with a hospital stay >14 days were high Na levels, NRL >18, high PCT levels and IL-6 >40 pg/mL. On multivariable analysis, the following factors remained significantly associated with prolonged LoS: older age (RR 1.015 per year of age; 95% confidence interval (CI) 1.005 - 1.024); hypernatraemia (RR 1.80; 95% CI 1.25 - 2.60); hyperkalaemia (RR 1.61; 95% CI 1.23 - 2.11); male sex (RR 1.30; 95% CI 1.07 - 1.57); and neutrophilia (RR 1.47; 95% CI 1.15 - 1.88).

Conclusions. COVID-19 pandemic preparedness requires hospital-based inpatient care to be prioritised in resource-limited settings, and availability of beds and prompt admissions are essential to ensure good clinical outcomes. In this study of COVID-19 patients admitted with pneumonia, multivariable analysis showed older age, hypernatraemia, hyperkalaemia and neutrophilia to be associated with LoS >14 days. This may assist with healthcare systems planning.
ted C-reactive protein (CRP) levels have all been associated with increased severity of disease and mortality in COVID-19.\textsuperscript{[7-9]} There is currently limited information on the value of laboratory parameters in predicting LoS in COVID-19. Reports have suggested that elevated serum aspartate aminotransferase (AST) and increased admission serum creatinine (sCr) may be associated with longer hospital stay.\textsuperscript{[10,11]}

**Objectives**

To identify laboratory admission parameters that could potentially predict longer hospital stay in patients admitted for COVID-19 pneumonia.

**Methods**

**Study setting and design**

A retrospective, cross-sectional study design was used to conduct a secondary analysis of data from a private laboratory in Gauteng Province, SA. Data were obtained from six hospitals to which a total of 642 adults (aged >18 years) were admitted for the management of pneumonia during the period 8 April - 18 November 2020. All patients were admitted for suspected or confirmed COVID-19 pneumonia and all underwent reverse transcription polymerase chain reaction (RT-PCR) testing.

**Sample size**

Based on a 20% prevalence of risk factors, an incidence of longer LoS of 35% and the estimation of relative risk (RR) of ≥1.5 with 80% power at the 5% significance level, a minimum sample size of 660 was required.\textsuperscript{12} The actual sample size of 642 was therefore adequate for a study of this nature.

**Data acquisition and variables**

We requested admission laboratory parameters of survivors only, therefore excluding patients who died during their hospital stay. As this was a secondary analysis, we did not have access to patient clinical records and we did not analyse COVID-19 symptoms, specific intensive care unit (ICU) stay or severity of illness. Laboratory staff transferred the relevant data to an Excel spreadsheet, version 2016 (Microsoft, USA), and each patient was allocated an identification number. Only de-identified data were supplied to the investigators. The various laboratory test requirements were determined by the attending clinician. We considered admission laboratory parameters to be those that were obtained during the week preceding admission, on the day of admission and 24 hours after admission.

The following variables were analysed: age, sex, LoS in days from admission to discharge, SARS-CoV-2 RT-PCR test result, serum interleukin-6 (IL-6), glycated haemoglobin (HbA1c), total serum cholesterol (TC), N-terminal pro b-type natriuretic peptide (NT-pro BNP), high-sensitivity cardiac troponin I, serum urea, sCr, sodium (Na), potassium (K), chloride (Cl), total carbon dioxide, estimated glomerular filtration rate (eGFR), white blood cell (WBC) count, lymphocytes, neutrophils, eosinophils, platelets, neutrophil-to-lymphocyte ratio (NLR), CRP, D-dimers and procalcitonin (PCT).

**Data analysis**

Pre-admission, admission and 24-hour post-admission laboratory data were available for some variables, and where more than one value existed, the admission values of the biomarkers were used. Laboratory data were categorised into normal, high and low according to standard reference ranges for the laboratory (Table 1). We divided IL-6 into four categories (<10, 10 - 20, 21 - 40 and >40 pg/mL, as all the values were above normal. The NLR was classified into normal (<6), mild (6 - <9), moderate (9 - 18) and severe (>18).\textsuperscript{13} Laboratory parameters for which <30% of the study group were tested were excluded from analysis, i.e. HbA1c, TC, CRP and NT-pro BNP. Based on a recent review indicating that the average LoS for COVID-19 patients was 14 days, we categorised LoS as ≤14 days and >14 days for this analysis.\textsuperscript{14}

We compared variables in RT-PCR-positive and negative patients. The association between study variables and RT-PCR status was determined by the χ² test for categorical variables (Fisher’s exact test was used for 2 × 2 tables), and the Wilcoxon rank-sum test was used for age.

The RR of each study variable for prolonged LoS was determined, together with its 95% confidence interval (CI), using binomial regression. Categories with n<15 overall were not included in the analyses (no reliable inference can be made based on such small groups). For multivariable analysis, only those analytes commonly analysed together (the full blood count and urea and electrolytes groups) were considered, together with age and sex. Study variables significant at p<0.20 were combined into a multivariable model, after examining each pair of variables for possible confounding using the χ² test (or Fisher’s exact test for 2 × 2 tables); a value of Cramer’s V (or the phi coefficient for Fisher’s exact test) >0.60 was regarded as too strong an association to include both variables in a multivariable model. sCr and eGFR were strongly associated (eGFR was used), as were WBCs and neutrophils (neutrophils were used). Non-significant variables were sequentially removed from the multivariable model. These analyses were conducted for the COVID-positive group and for the whole study group. Data analysis was carried out using SAS version 9.4 for Windows (SAS Institute, USA). A 5% significance level was used.

**Ethics approval**

The study was approved by the Sefako Makgatho Health Sciences University Research Ethics Committee (ref. no. SMUREC/D/187/2020(J)).

**Results**

This study describes demographic and laboratory parameters of 642 patients admitted to hospital for management of pneumonia (total group). Of these, 497 patients had a positive SARS-CoV-2 RT-PCR test confirming COVID-19 infection. Comparing the total group, the RT-PCR-negative group and the RT-PCR-positive group (Table 2), 34.6% (n=208), 31.7% (n=157) and 35.4% (n=51), respectively, were admitted to hospital for >14 days; the median (interquartile range) age in the total group, the RT-PCR-negative group and the RT-PCR-positive group was 58 (47 - 68) years, 49 (47 - 71) years and 57 (47 - 67) years, respectively, and the relative proportion of males was 52.6%, 52.4% and 52.8%, respectively. In terms of laboratory parameter comparison, only eosinopenia and lymphopenia were significantly prevalent in the RT-PCR-positive group compared with the RT-PCR-negative group: 62.6% v. 28.5% (p<0.001) and 46.6% v. 34.6% (p=0.0085), respectively. There were no significant between-group differences for any other parameter. A positive RT-PCR test obtained 26 days prior to admission was associated with shorter hospital LoS for the whole group (RR 0.48; 95% CI 0.25 - 0.93) (Table 2) and for those with confirmed COVID-19 infection (RR 0.31; 95% CI 0.12 - 0.80) (Table 1).

**Uni- and multivariable analysis of all admissions for pneumonia (N=642)** (Table 2). With univariable analysis, the following factors were significantly associated with prolonged hospital LoS: older
| Table 1. Age, sex, timing of RT-PCR test and admission laboratory parameters of the RT-PCR-positive group admitted with COVID-19 pneumonia |
|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
| Variables                     | Total (N=497), n (%)          | ≤14 days (N=321), n (%)       | >14 days (N=176), n (%)       | RR for longer LoS (95% CI) |
| Age (years)                   |                               |                               |                               |                             |
| Median (IQR)                  | 57 (47 - 67)                  | 55 (45 - 64)                  | 61 (53 - 69)                  | 1.016 (1.008 - 1.024)*      |
| Sex                           |                               |                               |                               |                             |
| Female                        | 235 (47.3)                    | 164 (69.8)                    | 71 (30.2)                     | 1.00 (ref.)                 |
| Male                          | 262 (52.7)                    | 157 (59.9)                    | 105 (40.1)                    | 1.33 (1.04 - 1.69)*         |
| Days from COVID-19 test to admission (n=385) |                               |                               |                               |                             |
| Same day                      | 172 (44.7)                    | 116 (67.4)                    | 56 (32.6)                     | 1.00 (ref.)                 |
| 1                             | 97 (25.2)                     | 66 (68.0)                     | 31 (32.0)                     | 0.98 (0.68 - 1.41)          |
| 2 - 5                         | 76 (19.7)                     | 54 (71.1)                     | 22 (28.9)                     | 0.89 (0.59 - 1.34)          |
| ≥6                            | 40 (10.4)                     | 36 (90.0)                     | 4 (10.0)                      | 0.31 (0.12 - 0.80)*         |
| Laboratory parameters         |                               |                               |                               |                             |
| Na (mmol/L) (n=453)           |                               |                               |                               |                             |
| Low                           | 115 (25.3)                    | 68 (59.1)                     | 47 (40.8)                     | 1.28 (0.98 - 1.68)          |
| Normal (136 - 145)            | 323 (71.3)                    | 220 (68.1)                    | 103 (31.8)                    | 1.00 (ref.)                 |
| High                          | 15 (3.3)                      | 5 (33.3)                      | 10 (66.6)                     | 2.09 (1.41 - 3.09)*         |
| K (mmol/L) (n=452)            |                               |                               |                               |                             |
| Low                           | 38 (8.4)                      | 24 (63.1)                     | 14 (36.8)                     | 1.11 (0.72 - 1.73)          |
| Normal (3.5 - 5.1)            | 375 (82.9)                    | 251 (66.9)                    | 124 (33)                      | 1.00 (ref.)                 |
| High                          | 39 (8.6)                      | 17 (43.5)                     | 22 (56.4)                     | 1.71 (1.25 - 2.33)*         |
| Cl (mmol/L) (n=453)           |                               |                               |                               |                             |
| Low                           | 55 (12.1)                     | 32 (58.1)                     | 23 (41.8)                     | 1.36 (0.96 - 1.93)          |
| Normal (98 - 108)             | 335 (73.9)                    | 232 (69.2)                    | 103 (30.7)                    | 1.00 (ref.)                 |
| High                          | 63 (13.9)                     | 29 (46)                       | 34 (53.9)                     | 1.76 (1.32 - 2.32)*         |
| PCO₂ (mmol/L) (n=452)         |                               |                               |                               |                             |
| Low                           | 305 (67.4)                    | 191 (62.6)                    | 114 (37.3)                    | 1.21 (0.91 - 1.60)          |
| Normal (22 - 28)              | 142 (31.4)                    | 98 (69)                       | 44 (30.9)                     | 1.00 (ref.)                 |
| High                          | 5 (1.1)                       | 3 (60)                        | 2 (40)                        |                          |
| Urea (mmol/L) (n=451)         |                               |                               |                               |                             |
| Low                           | 36 (7.9)                      | 31 (86.1)                     | 5 (13.8)                      | 0.45 (0.20 - 1.04)          |
| Normal (2.9 - 8.2)            | 267 (59.2)                    | 185 (69.2)                    | 82 (30.7)                     | 1.00 (ref.)                 |
| High                          | 148 (32.8)                    | 75 (50.6)                     | 73 (49.3)                     | 1.61 (1.26 - 2.05)*         |
| sCr (µmol/L) (n=455)          |                               |                               |                               |                             |
| Low                           | 127 (27.9)                    | 89 (70)                       | 38 (29.9)                     | 0.92 (0.66 - 1.28)          |
| Normal (71 - 115)             | 213 (46.8)                    | 144 (67.6)                    | 69 (32.3)                     | 1.00 (ref.)                 |
| High                          | 115 (25.2)                    | 62 (53.9)                     | 53 (46)                       | 1.42 (1.08 - 1.88)*         |
| eGFR (mL/min) (n=451)         |                               |                               |                               |                             |
| Moderate to severe decrease (<45) | 95 (21.06)                   | 48 (50.52)                    | 47 (49.47)                    | 1.68 (1.22 - 2.32)*         |
| Moderate decrease (45 - 59)   | 50 (11.08)                    | 27 (54)                       | 23 (46)                       | 1.56 (1.06 - 2.31)*         |
| Mild decrease (60 - 89)       | 160 (35.47)                   | 114 (71.25)                   | 46 (28.75)                    | 0.98 (0.69 - 1.39)          |
| Normal (≥90)                  | 146 (32.37)                   | 103 (70.54)                   | 43 (29.45)                    | 1.00 (ref.)                 |
| WBCs (× 10⁹/L) (n=450)        |                               |                               |                               |                             |
| Low                           | 48 (10.66)                    | 32 (66.66)                    | 16 (33.33)                    | 1.10 (0.71 - 1.69)          |
| Normal (4 - 10)               | 299 (66.44)                   | 208 (69.56)                   | 91 (30.43)                    | 1.00 (ref.)                 |
| High                          | 103 (22.88)                   | 52 (50.48)                    | 51 (49.51)                    | 1.63 (1.25 - 2.11)*         |
| Neutrophils (× 10⁹/L) (n=446)  |                               |                               |                               |                             |
| Low                           | 27 (6.05)                     | 20 (74.07)                    | 7 (25.92)                     | 0.90 (0.46 - 1.75)          |
| Normal (2 - 7)                | 285 (63.9)                    | 203 (71.22)                   | 82 (28.77)                    | 1.00 (ref.)                 |
| High                          | 134 (30.04)                   | 67 (50)                       | 67 (50)                       | 1.74 (1.35 - 2.23)*         |
| Lymphocytes (× 10⁹/L) (n=446)  |                               |                               |                               |                             |
| Low                           | 199 (44.61)                   | 114 (57.28)                   | 85 (42.71)                    | 1.49 (1.16 - 1.93)*         |
| Normal (1 - 3)                | 245 (54.93)                   | 175 (71.42)                   | 70 (28.57)                    | 1.00 (ref.)                 |
| High                          | 2 (0.44)                      | 1 (50)                        | 1 (50)                        |                          |

Continued ...
IN PRACTICE

Table 1. (continued) Age, sex, timing of RT-PCR test and admission laboratory parameters of the RT-PCR-positive group admitted with COVID-19 pneumonia

| Variables          | Total (N=497), n (%) | ≤14 days (N=321), n (%) | >14 days (N=176), n (%) | RR for longer LoS (95% CI) |
|--------------------|----------------------|-------------------------|-------------------------|---------------------------|
| Eosinophils (× 10^9/L) (n=446) |                       |                         |                         |                           |
| Low                | 279 (62.55)          | 166 (59.49)             | 113 (40.5)              | 1.32 (0.93 - 1.88)        |
| Normal (0.02 - 0.5)| 85 (19.05)           | 59 (69.41)              | 26 (30.58)              | 1.00 (ref.)               |
| High               | 82 (18.38)           | 65 (79.26)              | 17 (20.73)              | 0.68 (0.40 - 1.15)        |
| Platelets (× 10^9/L) (n=448) |                       |                         |                         |                           |
| Low                | 66 (14.73)           | 41 (62.12)              | 25 (37.87)              | 1.10 (0.79 - 1.55)        |
| Normal (150 - 450) | 367 (81.91)          | 241 (65.66)             | 126 (34.33)             | 1.00 (ref.)               |
| High               | 15 (3.34)            | 8 (53.33)               | 7 (46.66)               | 1.36 (0.78 - 2.38)        |
| NLR (n=446)        |                       |                         |                         |                           |
| Normal (<6)        | 247 (55.38)          | 183 (74.08)             | 64 (25.91)              | 1.00 (ref.)               |
| Mild (6 - <9)      | 66 (14.79)           | 40 (60.6)               | 26 (39.39)              | 1.52 (1.05 - 2.19)*       |
| Moderate (9 - 18)  | 106 (23.76)          | 56 (52.83)              | 50 (47.16)              | 1.82 (1.36 - 2.44)*       |
| Severe (>18)       | 27 (6.05)            | 11 (40.74)              | 16 (59.25)              | 2.29 (1.57 - 3.33)*       |
| D-dimers (ng/mL) (n=343) |                   |                         |                         |                           |
| Normal (≤0.5)      | 72 (20.99)           | 58 (80.55)              | 14 (19.44)              | 1.00 (ref.)               |
| High (>0.5)        | 271 (79)             | 178 (65.68)             | 93 (34.31)              | 1.76 (1.07 - 2.90)*       |
| PCT (ng/mL) (n=306) |                       |                         |                         |                           |
| Normal (0 - 0.05)  | 81 (26.47)           | 69 (85.18)              | 12 (14.81)              | 1.00 (ref.)               |
| High               | 225 (73.52)          | 129 (57.33)             | 96 (42.66)              | 2.88 (1.67 - 4.96)*       |
| IL-6 (pg/mL) (n=298) (all abnormal) |                  |                         |                         |                           |
| <10                | 89 (29.86)           | 77 (86.51)              | 12 (13.48)              | 1.00 (ref.)               |
| 10 - 20            | 43 (14.42)           | 33 (76.74)              | 10 (23.25)              | 1.72 (0.81 - 3.67)        |
| 21 - 40            | 64 (21.47)           | 50 (78.12)              | 14 (21.87)              | 1.62 (0.80 - 3.27)        |
| >40                | 102 (34.22)          | 60 (58.82)              | 42 (41.17)              | 3.05 (1.72 - 5.43)*       |
| HS cTnI (ng/L) (n=225) |                    |                         |                         |                           |
| Normal (<34)       | 156 (72.22)          | 148 (94.87)             | 71 (45.51)              | 1.00 (ref.)               |
| High (≥34)         | 60 (27.77)           | 44 (73.33)              | 35 (26.67)              | 1.25 (0.88 - 1.79)        |

RT-PCR = reverse transcription polymerase chain reaction; RR = relative risk; LoS = length of stay; CI = confidence interval; IQR = interquartile range; Na = sodium; K = potassium; Cl = chloride; PCO$_2$ = partial pressure of carbon dioxide; sCr = serum creatinine; eGFR = estimated glomerular filtration rate; WBCs = white blood cells; NLR = neutrophil-to-lymphocyte ratio; PCT = procalcitonin; IL-6 = interleukin-6; HS cTnI = high-sensitivity cardiac troponin I.

*Statistically significant.

age, male sex, high sCr levels, high urea, high K, Na and Cl levels, low eGFR (<60 mL/min/1.73 m$^2$), low WBC count, lymphopenia, neutrophilia, NLR ≥6, high D-dimer levels, high PCT, and IL-6 >40 pg/mL. The corresponding RRs with 95% CIs are detailed in Table 2. Multivariable analysis identified increased age (RR 1.015 per year; 95% CI 1.005 - 1.024), hypernatraemia (RR 1.61; 95% CI 1.18 - 2.20) and neutrophilia (RR 1.47; 95% CI 1.15 - 1.88) were associated with prolonged hospital LoS.

Table 2. Multivariable analysis identified increased age (RR 1.015 per year; 95% CI 1.005 - 1.024), hypernatraemia (RR 1.40; 95% CI 1.08 - 1.82) and neutrophilia, NLR ≥6, high D-dimer levels, high PCT, and IL-6 >40 pg/mL. The corresponding RRs with 95% CIs are detailed in Table 1. With multivariable analysis, older age (but not sex) (RR 1.015 per year; 95% CI 1.005 - 1.024), hypernatraemia (RR 1.80; 95% CI 1.25 - 2.60), hyperkalaemia (RR 1.61; 95% CI 1.18 - 2.20) and neutrophilia (RR 1.47; 95% CI 1.15 - 1.88) were associated with increased hospital LoS (Table 3).

Discussion

This is the first study from SA to identify factors associated with prolonged LoS in adults hospitalised for COVID-19 infection. Multivariable analysis showed that older age, high Na, high K and neutrophilia were independently associated with a long hospital stay. On univariate analysis, IL-6 >40 pg/mL, high PCT and high NLR correlated with an RR >2.0. We considered all of these variables to be predictive of LoS >14 days.

Current reports often do not use LoS as the primary measure of outcome, and include disease severity, ICU stay or mortality as adjunctive outcomes. Alwafi et al.[11] identified age and end-stage renal failure as affecting mortality and hospital stay. A further report[11] indicated that abnormal liver function is common in COVID-19 and that a higher AST level is associated with a longer hospital stay. The practical implications of these findings were not clearly elucidated. A recent review indicated that LoS in patients who die of COVID-19 is shorter than in survivors. Analysing hospital stay as a primary outcome measure is therefore likely to provide salient information. In our report, we excluded patients who had died and therefore anticipated that long LoS would be likely to correlate with disease severity.

We identified that older age was associated with a hospital stay of >14 days. The higher prevalence of comorbid conditions in older individuals has been associated with severe COVID-19.[17-19]
Table 2. Age, sex, timing of RT-PCR test and admission laboratory parameters of the whole study group

| Variables                              | Total (N=642), n (%) | ≤14 days (N=420), n (%) | >14 days (N=222), n (%) | RR for longer LoS (95% CI) |
|----------------------------------------|----------------------|-------------------------|-------------------------|----------------------------|
| Age (years)                            |                      |                         |                         |                            |
| Median (IQR)                           | 58 (47 - 68)         | 55 (45 - 65)            | 63 (53 - 71)            | 1.016 (1.009 - 1.023)*     |
| Sex                                    |                      |                         |                         |                            |
| Female                                 | 304 (47.35)          | 214 (70.39)             | 90 (29.6)               | 1.00 (ref.)                |
| Male                                   | 338 (52.64)          | 206 (60.94)             | 132 (39.05)             | 1.32 (1.06 - 1.64)*        |
| COVID status                           |                      |                         |                         |                            |
| Negative                               | 145 (22.58)          | 99 (68.27)              | 46 (31.72)              | 1.00 (ref.)                |
| Positive                               | 497 (77.41)          | 321 (64.58)             | 176 (35.41)             | 1.12 (0.85 - 1.46)         |
| Days from COVID-19 test to admission (n=530) |                   |                         |                         |                            |
| Same day                               | 260 (49.05)          | 181 (69.61)             | 79 (30.38)              | 1.00 (ref.)                |
| 1                                      | 129 (24.33)          | 86 (66.66)              | 43 (33.33)              | 1.097 (0.808 - 1.489)      |
| 2 - 5                                  | 86 (16.22)           | 57 (66.27)              | 29 (33.72)              | 1.109 (0.783 - 1.572)      |
| ≥6                                     | 55 (10.37)           | 47 (85.45)              | 8 (14.54)               | 0.48 (0.25 - 0.93)*        |
| Laboratory parameters                  |                      |                         |                         |                            |
| Na (mmol/L) (n=585)                    |                      |                         |                         |                            |
| Low                                    | 156 (26.66)          | 93 (59.61)              | 63 (40.38)              | 1.29 (1.02 - 1.64)*        |
| Normal (136 - 145)                     | 413 (70.59)          | 284 (68.76)             | 129 (31.23)             | 1.00 (ref.)                |
| High                                   | 16 (2.73)            | 6 (37.5)                | 10 (62.5)               | 2.00 (1.33 - 3.00)*        |
| K (mmol/L) (n=584)                     |                      |                         |                         |                            |
| Low                                    | 50 (8.56)            | 32 (64)                 | 18 (36)                 | 1.11 (0.75 - 1.65)         |
| Normal (3.5 - 5.1)                     | 482 (82.53)          | 326 (67.63)             | 156 (32.36)             | 1.00 (ref.)                |
| High                                   | 52 (8.9)             | 24 (46.15)              | 28 (53.84)              | 1.66 (1.25 - 2.21)*        |
| CI (mmol/L) (n=585)                    |                      |                         |                         |                            |
| Low                                    | 73 (12.47)           | 42 (57.53)              | 31 (42.46)              | 1.39 (1.03 - 1.88)*        |
| Normal (98 - 108)                      | 429 (73.33)          | 298 (69.46)             | 131 (30.53)             | 1.00 (ref.)                |
| High                                   | 83 (14.18)           | 43 (51.8)               | 40 (48.19)              | 1.58 (1.21 - 2.06)*        |
| PCO₂ (mmol/L) (n=584)                  |                      |                         |                         |                            |
| Low                                    | 400 (68.49)          | 254 (63.5)              | 146 (36.5)              | 1.20 (0.93 - 1.56)         |
| Normal (22 - 28)                       | 178 (30.47)          | 124 (69.66)             | 54 (30.33)              | 1.00 (ref.)                |
| High                                   | 6 (1.02)             | 4 (66.66)               | 2 (33.33)               | -                          |
| Urea (mmol/L) (n=583)                  |                      |                         |                         |                            |
| Low                                    | 47 (8.06)            | 39 (82.97)              | 8 (17.02)               | 0.57 (0.30 - 1.09)         |
| Normal (2.9 - 8.2)                     | 344 (59)             | 241 (70.05)             | 103 (29.94)             | 1.00 (ref.)                |
| High                                   | 192 (32.93)          | 101 (52.6)              | 91 (47.39)              | 1.58 (1.27 - 1.97)*        |
| sCr (µmol/L) (n=587)                   |                      |                         |                         |                            |
| Low                                    | 173 (29.47)          | 126 (72.83)             | 47 (27.16)              | 0.83 (0.62 - 1.13)         |
| Normal (71 - 115)                      | 261 (44.66)          | 176 (67.43)             | 85 (32.56)              | 1.00 (ref.)                |
| High                                   | 153 (26.06)          | 83 (54.24)              | 70 (45.75)              | 1.40 (1.10 - 1.80)*        |
| eGFR (mL/min) (n=580)                  |                      |                         |                         |                            |
| Moderate to severe decrease (<45)      | 127 (21.89)          | 67 (52.75)              | 60 (47.24)              | 1.77 (1.31 - 2.39)*        |
| Moderate decrease (45 - 59)            | 64 (11.03)           | 31 (48.43)              | 33 (51.56)              | 1.93 (1.38 - 2.70)*        |
| Mild decrease (60 - 89)                | 202 (34.82)          | 145 (71.78)             | 57 (28.21)              | 1.06 (0.76 - 1.46)         |
| Normal (≥90)                           | 187 (32.24)          | 137 (73.26)             | 50 (26.73)              | 1.00 (ref.)                |
| WBCs (× 10⁹/L) (n=583)                 |                      |                         |                         |                            |
| Low                                    | 56 (9.6)             | 38 (67.85)              | 18 (32.14)              | 1.04 (0.69 - 1.57)         |
| Normal (4 - 10)                        | 392 (67.23)          | 271 (69.13)             | 121 (30.86)             | 1.00 (ref.)                |
| High                                   | 135 (23.15)          | 75 (55.55)              | 60 (44.44)              | 1.44 (1.13 - 1.83)*        |
| Neutrophils (× 10⁹/L) (n=576)          |                      |                         |                         |                            |
| Low                                    | 30 (5.2)             | 22 (73.33)              | 8 (26.66)               | 0.91 (0.49 - 1.68)         |
| Normal (2 - 7)                         | 371 (64.4)           | 262 (70.61)             | 109 (29.38)             | 1.00 (ref.)                |
| High                                   | 175 (30.38)          | 96 (54.83)              | 79 (45.14)              | 1.54 (1.22 - 1.93)*        |

Continued ...
However, exaggerated immune responses, increased intravascular coagulation, decreased physiological capacity, decreased functional reserve and declining immunity are all associated with increasing age and severe COVID-19. We found that an NLR of >18 was associated with a hospital stay of >14 days. The NLR has been used as a marker of inflammation and may be predictive of clinical outcomes in systemic illnesses such as cardiovascular disease, cancer and pancreatitis. A systematic review of the NLR in COVID-19 and an article by Cavalcante-Silva et al. confirmed its predictive value in identifying severe cases early on. Similarly, neutrophils have been associated with severe COVID-19 and poor outcomes. Studies indicate that neutrophil activation and degranulation are processes that occur in severe acute respiratory syndrome and may enhance antiviral defences. In the present study, high PCT was associated with a hospital stay of >14 days. PCT is a propeptide of calcitonin, which is usually produced by the thyroid tissue and is not associated with hormonal activity. During bacterial infection, PCT may be produced by extra-thyroid tissue and acts as a mediator of inflammation. It has been shown that in severe COVID-19, PCT may be markedly increased.

### Table 2. (continued) Age, sex, timing of RT-PCR test and admission laboratory parameters of the whole study group

| Variables                     | Total (N=642), n (%) | ≤14 days (N=420), n (%) | >14 days (N=222), n (%) | RR for longer LoS (95% CI) |
|-------------------------------|----------------------|-------------------------|-------------------------|---------------------------|
| Lymphocytes (× 10^9/L)        |                      |                         |                         |                          |
| Low                           | 244 (42.36)          | 142 (58.19)             | 102 (41.8)              | 1.47 (1.17 - 1.84)*       |
| Normal (1 - 3)                | 326 (56.59)          | 233 (71.47)             | 93 (28.52)              | 1.00 (ref.)               |
| High                          | 6 (1.04)             | 5 (83.33)               | 1 (16.66)               |                          |
| Eosinophils (× 10^9/L)        |                      |                         |                         |                          |
| Low                           | 316 (54.86)          | 193 (61.07)             | 123 (38.92)             | 1.21 (0.90 - 1.63)        |
| Normal (0.02 - 0.5)           | 115 (19.96)          | 78 (67.82)              | 37 (32.17)              | 1.00 (ref.)               |
| High                          | 145 (25.17)          | 109 (75.17)             | 36 (24.82)              | 0.77 (0.52 - 1.14)        |
| Platelets (× 10^9/L)          |                      |                         |                         |                          |
| Low                           | 76 (13.1)            | 45 (59.21)              | 31 (40.78)              | 1.23 (0.91 - 1.65)        |
| Normal (150 - 450)            | 484 (83.44)          | 323 (66.73)             | 161 (33.26)             | 1.00 (ref.)               |
| High                          | 20 (3.44)            | 13 (65)                 | 7 (35)                  | 1.05 (0.57 - 1.94)        |
| NLR (n=576)                   |                      |                         |                         |                          |
| Normal (<6)                   | 324 (56.25)          | 238 (73.45)             | 86 (26.54)              | 1.00 (ref.)               |
| Mild (6 - <9)                 | 79 (13.71)           | 50 (63.29)              | 29 (36.7)               | 1.38 (0.98 - 1.95)        |
| Moderate (9 - 18)             | 136 (23.61)          | 76 (55.88)              | 60 (44.11)              | 1.66 (1.28 - 2.16)*       |
| Severe (>18)                  | 37 (6.42)            | 16 (43.24)              | 21 (56.75)              | 2.14 (1.53 - 2.99)*       |
| D-dimers (ng/mL) (n=427)      |                      |                         |                         |                          |
| Normal (≤0.5)                 | 94 (22.01)           | 76 (80.85)              | 18 (19.14)              | 1.00 (ref.)               |
| High (>0.5)                   | 333 (77.98)          | 227 (68.16)             | 106 (31.83)             | 1.66 (1.07 - 2.59)        |
| PCT (ng/mL) (n=395)           |                      |                         |                         |                          |
| Normal (0 - 0.05)             | 108 (27.34)          | 93 (86.11)              | 15 (13.88)              | 1.00 (ref.)               |
| High                          | 287 (72.65)          | 168 (58.53)             | 119 (41.46)             | 2.99 (1.83 - 4.87)*       |
| IL-6 (pg/mL) (n=383) (all abnormal) |             |                         |                         |                          |
| <10                           | 125 (32.63)          | 111 (88.8)              | 14 (11.2)               | 1.00 (ref.)               |
| 10 - 20                       | 56 (14.62)           | 45 (80.35)              | 11 (19.64)              | 1.75 (0.85 - 3.62)        |
| 21 - 40                       | 74 (19.32)           | 59 (79.72)              | 15 (20.27)              | 1.81 (0.93 - 3.53)        |
| >40                           | 128 (33.42)          | 78 (60.93)              | 50 (39.06)              | 3.487 (2.03 - 5.98)*      |
| HS cTnI (ng/L) (n=298)        |                      |                         |                         |                          |
| Normal (<34)                  | 219 (73.48)          | 148 (67.57)             | 71 (32.42)              | 1.00 (ref.)               |
| High (≥34)                    | 79 (26.51)           | 44 (55.69)              | 35 (44.3)               | 1.37 (1.00 - 1.87)        |

RT-PCR = reverse transcription polymerase chain reaction; RR = relative risk; LoS = length of stay; CI = confidence interval; IQR = interquartile range; Na = sodium; K = potassium; CI = chloride; PCO₂ = partial pressure of carbon dioxide; sCr = serum creatinine; eGFR = estimated glomerular filtration rate; WBCs = white blood cells; NLR = neutrophil-to-lymphocyte ratio; PCT = procalcitonin; IL-6 = interleukin-6; HS cTnI = high-sensitivity cardiac troponin I.

*Statistically significant.

### Table 3. Multivariable parameters in the RT-PCR-positive group (N=432)

| Variable | Category | RR (95% CI for RR) |
|----------|----------|-------------------|
| Age      | n/a      | 1.015/year (1.005 - 1.024) |
| Na (mmol/L) | High >145 | 1.80 (1.25 - 2.60) |
| K (mmol/L) | High >5.1 | 1.61 (1.18 - 2.20) |
| Neutrophils (× 10^9/L) | High >7 | 1.47 (1.15 - 1.88) |

RT-PCR = reverse transcription polymerase chain reaction; RR = relative risk; CI = confidence interval; n/a = not applicable.
Similarly, we found a correlation between Hypotheses implicate the syndrome of inappropriate the cytokine storm. We found that IL-6 >40 pg/mL was associated with a hospital stay >14 days. In addition to the prognostic value of IL-6, an elevated level of >10 pg/mL has been associated with the cytokine storm. The airway epithelium is one of the first lines of defence in SARS-CoV-2 infection. A complex mechanism results in the release of cytokines (e.g. IL-6) by activated alveolar macrophages, thereby triggering an inflammatory response. Phagocytic disruption is thought to be associated with the cytokine storm. In the present study, 60% of patients who were COVID-19-positive had an admission IL-6 test. Of these, 34% fell into the >40 pg/mL range. The value of routine admission IL-6 testing and its predictive value in various COVID-19 outcomes requires evaluation in a larger study.

We found that high Na levels were associated with a hospital stay >14 days. Dysnatraemia in COVID-19 hospitalised patients has generally been associated with poorer outcomes. Both hypernatraemia and hyponatraemia, at admission, have been associated with increased mortality, ICU admission, longer hospitalisation and mechanical ventilation. Specifically, hyponatraemia was found to be relatively common in hospitalised COVID-19 patients and to be associated with severe illness and increased in-hospital mortality. On the contrary, admission hypernatraemia or the development of hypernatraemia during hospitalisation have been associated with increased mortality and death. Similarly, we found a correlation between hypernatraemia and a long hospital stay. It has been reported that SARS-CoV-2 binds to the angiotensin-converting enzyme 2 receptor in kidney tubules. The resulting high levels of angiotensin II may facilitate Na reabsorption, leading to hypernatraemia. In the context of admission hypernatraemia in COVID-19, it is currently uncertain what the role is of dehydration, advanced age and diarrhoea. This requires further investigation. However, low admission Na levels have also been reported in severe COVID-19. Hypotheses implicate the syndrome of inappropriate antidiuretic hormone secretion, intestinal injury and acute kidney injury. Larger studies are required to analyse the role and predictive value of dysnatraemia in subsets of COVID-19 patients.

Efforts to identify and correct dysnatraemia and other electrolyte imbalances as early as possible are prudent. These may potentially improve outcomes and also require further investigation.

Similar to dysnatraemia, high and low K levels have been associated with COVID-19. We identified high K to be associated with a hospital stay >14 days. In an editorial, Chan et al. reported the relatively common occurrence of hyperkalaemia in hospitalised COVID-19 patients and those with severe disease. The prolonged SARS-CoV-2 pandemic has resulted in the need for healthcare workers to predict bed capacity and to accommodate regular patients. Using laboratory parameters to predict LoS seems intuitive and requires further validation in the context of hospital protocols.

Study limitations
This study was conducted in the private healthcare sector and in a relatively small number of hospitals in Gauteng, which limits generalisability of the results. In addition, these data pertain to admissions for pneumonia, and in the absence of additional clinical data further inferences regarding the patients’ profile and severity of illness are limited. We were only able to analyse laboratory parameters that were supplied by the laboratory, and there was inevitable heterogeneity in the number of tests per patient. The diverse prevalence of laboratory tests for similar patient populations is usual in clinical situations and is based on physician preference. Nonetheless, it could have been a source of reporting bias, and other parameters may be predictive of LoS. A large study analysing these clinical symptoms, COVID-19 severity and ICU stay, together with biomarkers, would be helpful.

Conclusions
COVID-19 and the development of new strains of SARS-CoV-2 have disrupted healthcare systems around the world. Availability of beds and prompt admission, particularly during peaks of infection, are essential to ensure good clinical outcomes. In this study we identified older age, high Na, high K and high neutrophils (multivariable analysis) and NLR >18, high PCT and IL-6 >40 pg/mL (RR >2.0 univariate analysis) to be predictive of a hospital stay >14 days. This information may help health service providers to triage and better manage bed occupancy. Our findings that NLR, Na, K and neutrophils were predictive of LoS are relevant in the context of early bed allocation and resource planning. These parameters are almost routinely requested upon hospital admission, and are easily available and relatively inexpensive.

Declaration.
None.

Acknowledgements.
The authors express their appreciation to Jan Vermaak and his staff for supplying the laboratory data. They are also grateful to the Wits Donald Gordon Medical Centre Research Office for logistical support and for funding the statistical analysis.

Author contributions.
Conception /design of the work: JP, DB. Data collection/verification: JP, PPKM, DAIR, KSCM, NC, MM. Data analysis and interpretation: PG, JP. Drafting the article: JP, NC. Critical revision of the article: JP, PG. Final approval of the version to be published: JP, DB.

Funding.
None.

Conflicts of interest.
None.

1. World Health Organization. WHO coronavirus (COVID-19) dashboard. 2021. https://covid19.who.int/ (accessed 4 June 2021).
2. Xieck R. Pandemic and Lockdown: A territorial approach to COVID-19 in China, Italy and the United States. Eurasia Geol Econ 2020;6(14):5-43. https://doi.org/10.15877/2126.2020.1926103
3. Haider N, Osman AX, Gudurupi A, et al. Lockdown measures in response to COVID-19 in nine sub-Saharan African countries. BMJ Glob Health 2020;5:e003319. https://doi.org/10.1136/bmjghlth-2020-003319
4. Karim SA, de Oliveira T. New SARS-CoV-2 variants – clinical, public health, and vaccine implications. N Engl J Med 2021;384(19):1866-1868. https://doi.org/10.1056/NEJMe2100362
5. Dell’AI, Kahn D. Geographical maldistribution of surgical resources in South Africa: A review of the number of hospitals, hospital beds and surgical beds. S Afr Med J 2017;107(12):1099-1105. https://doi.org/10.7196/SAMJ.2017.v107i12.12539
6. Wolff I, Nee L, Hickey N, Marzollik M. Risk factors for COVID-19 severity and fatality: A structured literature review. Infect Def J 2020;49(1):1-28. https://doi.org/10.1093/infdis/jiaa674
7. Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in-hospital mortality in patients with COVID-19. J Thromb Haemost 2020;18(6):1324-1329. https://doi.org/10.1111/jth.14809
8. Malik P, Patel U, Mehta D, et al. Biomarkers and outcomes of COVID-19 hospitalisations: Systematic review and meta-analysis. BMJ Evid Based Med 2021;26(3):1-12. https://doi.org/10.1136/bmjebm-2020-115360
9. Guo A, Iac L, Tan H, et al. Risk factors on admission associated with hospital length of stay in patients with COVID-19: A retrospective cohort study. Sci Rep 2021;11:7590. https://doi.org/10.1038/s41598-021-86853-4
IN PRACTICE

Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. Rev Cytogfr. 2020.05.009

IN PRACTICE

Gubernatorova EO, Gorshkova EA, Polinova AI, Drutskaya MS. IL-6: Relevance for immunopathology cytokine storm associated with SARS-CoV-2 infection. J Allergy Clin Immunol 2020;146(3):518-534.

IN PRACTICE

Copaescu A, Smibert O, Gibson A, Phillips EJ, Trubiano JA. The role of IL-6 and other mediators in the progression. Crit Rev Clin Lab Sci 2020;57(6):389-399.

IN PRACTICE

Vijayan AL, Vanimaya SR, Saikant R, et al. Procalcitonin: A promising diagnostic marker for sepsis in patients hospitalized with COVID-19. Nepal J Clin Epidemiol 2021;15(14):839-852.

IN PRACTICE

Ahrenfeldt LJ, Otavova M, Christensen K, Lindahl-Jacobsen R. Sex and age differences in COVID-19 mortality in Europe. Wien Klin Wochenschr 2020;133:393-398.

IN PRACTICE

Kim S, Eliot M, Koestler DC, Wu WC, Kelsey KT. Association of neutrophil-to-lymphocyte ratio with mortality in Europe. Wien Klin Wochenschr 2020;133:393-398.

IN PRACTICE

Worldometer. Age, sex, existing conditions of COVID-19 cases and deaths. 13 May 2020. https://www.worldometers.info/coronavirus/coronavirus-agex-condemographics/ (accessed 7 June 2021).

IN PRACTICE

Sjöström A, Rysz S, Sjöström H, et al. Hypernatremia is common in patients with severe COVID-19 and indicates a poor prognosis. Res Square 2021-17. https://doi.org/10.21037/res.2021-17

IN PRACTICE

Zimmer MA, Zunk AK, Weifer OW, et al. Hypernatremia – a manifestation of COVID-19: A case series. A&H Pract 2021;54:110-1295.

IN PRACTICE

Ruiz-Sánchez JG, Núñez-Gil EJ, Guotta M, et al. Prognostic impact of hypernatremia and hypocalcemia in COVID-19 pneumonia: A HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry analysis. Front Endocrinol 2020;11:599255. https://doi.org/10.3389/fendo.2020.599255

IN PRACTICE

Gheorghie G, Ike M, Rungar S, Sutan AMP, Bucialwa N, Dioume CC. Is there a relationship between COVID-19 and hypernatremia? Medscini (Kanoua) 2021;57(1):SS. https://doi.org/10.3930/mkds.57010SS

IN PRACTICE

Wu W, Le K, Li C, et al. Disorders of sodium balance and its clinical implications in COVID-19 patients: A multicenter retrospective study. Intern Emerg Med 2021;6:1503-855. https://doi.org/10.1186/s13054-020-03374-8

IN PRACTICE

Veis P, Frilec SC, Vogelander NR, Kazmaier KA, COVID-19 and dysnatremia: A comparison between COVID-19 and non-COVID-19 respiratory illness. SAGE Open Med 2021;9:2050312121102778.

IN PRACTICE

Hirsch JS, Uppal NN, Sharma P, et al. Prevalence and outcomes of hypernatremia and hypocalcemia in patients hospitalised with COVID-19. Nephrol Dial Transplant 2021;36(6):1135-1138. https://doi.org/10.1093/ndt/gfab607

IN PRACTICE

Atila C, Isidro CO, Bassetti S, et al. Prevalence and outcome of dysnatremia in patients with COVID-19 compared to controls. Eur J Endocrinol 2021;184(3):409-418. https://doi.org/10.1530/EJE-20-12474

IN PRACTICE

Pourfoulou M, Alibouma SM, Shahriam F, Kazuryan J, Hardar-Soudriyani R. Fluid and electrolyte disturbances in COVID-19 and their complications. Biomed Res Int 2021;2021:6667047. https://doi.org/10.1155/2021/6667047

IN PRACTICE

Tzelis P, Winter JA, Bagkeris E, et al. Dysnatremia is a predictor for morbidity and mortality in hospitalized patients with COVID-19. J Clin Endocrinol Metab 2021;106(6):1547-1648. https://doi.org/10.1210/clinems/dgab107

IN PRACTICE

Martino M, Falcioni P, Giacinto G, et al. Sodium alterations impair the prognosis of hospitalized patients with COVID-19 pneumonia. Endocr Connect 2021;10(1):1344-1351. https://doi.org/10.1530/EC-21-0411

IN PRACTICE

Berta A, Malandrinos D, Corcov G, et al. Serum sodium alterations in SARS-CoV-2 (COVID-19) infection: Impact on patient outcome. Eur J Endocrinol 2021;185(1):137-144. https://doi.org/10.1502/ eje-20-1448

IN PRACTICE

Saad G, Abdellatif AB, El Abd YH, et al. Disorders of sodium balance in COVID-19 patients: Two Tunisian patients report. Pan Afr Med J 2021;39:199. https://doi.org/10.11604/pamj.2021.39.199.27626

IN PRACTICE

Socha V. Rates of hyperkalemia in patients with AKI and COVID-19. Nephron Times, 16 December 2020. https://www.nephron.com/nephron/nephron-times-diseases-and-conditions/18-12-2020-rates-of-hyperkalemia-in-patients-with-aki-and-covid-19/ (accessed 7 June 2021).

IN PRACTICE

Chen L, Indu P, Nairkmar GN, COVID-19: ‘The kidneys tell a tale’. Am J Nephrol 2021;57(2):77-177. https://doi.org/10.1159/000110011.

IN PRACTICE

Gaetao A, Amatcha F, Francesco J, et al. Hypokalemia in patients with COVID-19. Clin Exp Nephrol 2021;25(6):481-489. https://doi.org/10.1007/s41681-019-01396-4

IN PRACTICE

Accepted 29 November 2021.